HAINS TEST MDR TB

Hains Test (MDR TB)

What it is

The Hains Test (MDR TB) is a rapid molecular diagnostic test, also known as a line probe assay, used to detect multidrug-resistant tuberculosis (MDR-TB). It identifies genetic mutations in Mycobacterium tuberculosis that confer resistance to isoniazid (INH) and rifampicin (RIF), the two most powerful first-line anti-TB drugs. By targeting specific gene mutations, the test provides results much faster than traditional culture-based drug susceptibility testing.

Uses

This test is used to:

• Detect MDR-TB early in patients with suspected drug resistance.
• Guide treatment by identifying resistance to first-line anti-TB drugs.
• Support TB control programs in high-burden areas for rapid case identification.
• Reduce diagnostic delays compared to conventional laboratory methods.

Symptoms That May Lead to the Test

Your doctor may order this test if you show clinical symptoms of tuberculosis such as a persistent cough lasting more than 2–3 weeks, chest pain, blood in sputum, weight loss, fever, or night sweats—especially if you have failed standard TB therapy, relapsed after prior treatment, or have been exposed to a known MDR-TB patient.

Abnormal Results

Positive Result: Indicates genetic mutations associated with resistance to isoniazid and/or rifampicin. This confirms MDR-TB and requires treatment with second-line anti-TB drugs.

Negative Result: Suggests no detectable resistance mutations to isoniazid or rifampicin. However, culture-based drug susceptibility testing may still be performed to rule out other resistance patterns.

Risks

The test requires a sputum or respiratory specimen. Risks are minimal and limited to routine sample collection, which may cause mild discomfort during sputum expectoration or bronchoscopy (in some cases). There are no risks from the molecular assay itself.